GHO Capital Raises €2.5B To Grow Healthcare Investments

Fund IV broadens GHO’s global investor base, attracting strong commitments from existing backers and over 30 new institutional investors across Europe, North America, Asia Pacific and the Middle East.

Mike Mortimer, Alan Mackay and Andrea Ponti, the Managing Partners at GHO Capital commented: “We are witnessing a golden era of healthcare innovation, driven by the convergence of advanced science, digital technologies, and data. GHO Capital is at the forefront, delivering strong returns while enabling better, faster and more accessible healthcare.

“Fund IV’s success against the backdrop of a challenging fundraising environment reflects confidence in our strategy, transatlantic reach and consistent track record of outperformance across the healthcare ecosystem.”

In 2025, Europe’s healthcare and HealthTech ecosystem continues to thrive across both early- and growth-stage segments.

Read Also - Main Capital Invests In French Logistics Software Firm Shippingbo

Recent notable fundraises include ViCentra (Netherlands, €72.4M) to advance its insulin-delivery platform, Teton.ai (Denmark, €17M) to scale AI-driven patient monitoring and RDS (France, €14M) to expand connected-patch production for remote care.

Digital health is also gaining momentum, with SheMed (UK, €43M) focusing on personalised women’s health and Juisci (France, €5.5M) developing an AI-powered knowledge platform for clinicians.

Amid this activity, GHO Capital’s €2.5B Fund IV marks a significant institutional commitment to European and transatlantic healthcare. While startups raise tens of millions in venture rounds, GHO’s new fund is designed to fuel mid-market growth and consolidation across BioPharma, MedTech, Life-Science Tools, and HealthTech.

“We are grateful for the trust from both existing and new investors as we partner with world-class management teams to build the next generation of healthcare leaders,” added the Managing Partners.

Founded in 2014, Global Healthcare Opportunities (GHO Capital) comprising GHO Capital Management Limited and GHO Capital Partners Advisory Ltd. is a specialist healthcare investment firm.

Fund IV, GHO’s largest fund to date and 25% bigger than its predecessor, brings total AUM to around €9 billion, establishing GHO as Europe’s largest healthcare-focused private equity firm.

The firm continues to target mid-market opportunities across the fast-growing BioPharma, MedTech, Advisory & Data, Life Science Tools & Diagnostics, and HealthTech sectors.

Since the close of GHO Capital III in 2021, the firm has expanded its transatlantic presence, adding 19 new hires and growing to a team of over 75 professionals supporting portfolio companies across Europe and the US.

In 2024, GHO further strengthened its leadership by appointing a new Partner and adding five Operating Partners and Senior Advisors, enhancing its thematic investment strategy with deep sector expertise and hands-on value creation experience.

About GHO Capital

GHO Capital is a leading European healthcare investment firm focused on scaling high-potential companies across BioPharma, MedTech, HealthTech, and Life Sciences.